دورية أكاديمية
Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study.
| العنوان: | Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study. |
|---|---|
| المؤلفون: | Amin H; Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hameda.amin@regionh.dk.; Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital, Copenhagen, Denmark. Hameda.amin@regionh.dk., Andersen SWM; Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital, Copenhagen, Denmark., Jensen SS; Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital, Copenhagen, Denmark.; Research Area Oral Surgery, Section for Oral Biology and Immunopathology, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Kofod T; Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital, Copenhagen, Denmark. |
| المصدر: | Oral and maxillofacial surgery [Oral Maxillofac Surg] 2024 Sep; Vol. 28 (3), pp. 1117-1125. Date of Electronic Publication: 2024 Feb 29. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101319632 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-1569 (Electronic) Linking ISSN: 18651550 NLM ISO Abbreviation: Oral Maxillofac Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin : Springer-Verlag |
| مواضيع طبية MeSH: | Bisphosphonate-Associated Osteonecrosis of the Jaw*/surgery , Bisphosphonate-Associated Osteonecrosis of the Jaw*/therapy , Conservative Treatment*, Humans ; Retrospective Studies ; Male ; Female ; Aged ; Middle Aged ; Treatment Outcome ; Aged, 80 and over ; Bone Density Conservation Agents/adverse effects ; Risk Factors ; Exostoses/surgery ; Adult ; Denmark |
| مستخلص: | Purpose: Tori and exostoses are considered risk factors for the development of medication-related osteonecrosis of the jaw (MRONJ). The aims of this study were to present the prevalence of MRONJ located at tori in the Copenhagen ONJ Cohort, evaluate the surgical treatment of MRONJ located at tori and explore trauma to tori as an additional risk factor in patients on antiresorptive medication. Methods: Data from a consecutive series of 506 patients with MRONJ (Copenhagen ONJ Cohort) were reviewed for the presence of tori and MRONJ located at tori. Demographic and medical data were analyzed, and healing outcomes and pain after the prophylactic removal of tori, surgical treatment of MRONJ located at tori, and conservative treatment of MRONJ located at tori were evaluated and compared using Fisher's exact test. Results: MRONJ located at tori was frequent and could be identified in 53% of the patients with tori, which accounts for a prevalence of 5.1% in the entire cohort. Of the 28 surgically treated patients, 27 (96.4%) healed uneventfully with no exposed bone after their first or second revision surgery. Fourteen (41.2%) patients with tori underwent therapeutic removal, eight (23.5%) underwent prophylactic removal, and six (17.6%) underwent both therapeutic and prophylactic removals. Two (33.3%) of the six conservatively treated patients healed spontaneously. Both treatment types resulted in a significant decrease in pain. Conclusion: Prophylactic and therapeutic surgical removal of tori are reliable treatments and should be considered if a patient's general health allows surgery. Trial Registration: The study was approved by the Regional Scientific Ethical Committee (H-6-2013-010) on November 20, 2013, and was retrospectively registered. (© 2024. The Author(s).) |
| References: | Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J (2014) Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol 25:iii124–iii137. https://doi.org/10.1093/annonc/mdu103. (PMID: 10.1093/annonc/mdu10324782453) Burkiewicz JS, Scarpace SL, Bruce SP (2009) Denosumab in osteoporosis and oncology. Ann Pharmacother 43:1445–1455. https://doi.org/10.1345/aph.1M102. (PMID: 10.1345/aph.1M10219622756) Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032–1045. https://doi.org/10.4065/83.9.1032. (PMID: 10.4065/83.9.103218775204) Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117. https://doi.org/10.1016/s0278-2391(03)00720-1. (PMID: 10.1016/s0278-2391(03)00720-112966493) Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534. https://doi.org/10.1016/j.joms.2004.02.004. (PMID: 10.1016/j.joms.2004.02.00415122554) Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7–14. https://doi.org/10.1200/jop.2006.2.1.7. (PMID: 10.1200/jop.2006.2.1.7208717292794643) Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. Aust Endod J 35:119–130. https://doi.org/10.1111/j.1747-4477.2009.00213.x. (PMID: 10.1111/j.1747-4477.2009.00213.x19961450) Schiodt M, Reibel J, Oturai P, Kofod T (2014) Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204–213. https://doi.org/10.1016/j.oooo.2013.10.010. (PMID: 10.1016/j.oooo.2013.10.01024332520) Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M (2018) Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 69:177–187. https://doi.org/10.1016/j.ctrv.2018.06.007. (PMID: 10.1016/j.ctrv.2018.06.00730055439) Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg 80:920–943. https://doi.org/10.1016/j.joms.2022.02.008. (PMID: 10.1016/j.joms.2022.02.00835300956) Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132. https://doi.org/10.1200/jco.2010.31.3304. (PMID: 10.1200/jco.2010.31.330421343556) Raje N, Terpos E, Willenbacher W et al (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 19:370–381. https://doi.org/10.1016/s1470-2045(18)30072-x. (PMID: 10.1016/s1470-2045(18)30072-x29429912) Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri D (2013) Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist 18:353–361. https://doi.org/10.1634/theoncologist.2012-0261. (PMID: 10.1634/theoncologist.2012-0261234048163639520) Coleman R, Finkelstein DM, Barrios C et al (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60–72. https://doi.org/10.1016/s1470-2045(19)30687-4. (PMID: 10.1016/s1470-2045(19)30687-431806543) Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427. https://doi.org/10.1056/NEJMoa1708322. (PMID: 10.1056/NEJMoa170832228892457) Hallmer F, Andersson G, Götrick B, Warfvinge G, Anderud J, Bjørnland T (2018) Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126:477–485. https://doi.org/10.1016/j.oooo.2018.08.015. (PMID: 10.1016/j.oooo.2018.08.01530249535) Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24:945–952. https://doi.org/10.1200/jco.2005.04.2465. (PMID: 10.1200/jco.2005.04.246516484704) Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23. https://doi.org/10.1002/jbmr.2405. (PMID: 10.1002/jbmr.240525414052) Viviano M, Rossi M, Cocca S (2017) A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 43:120–124. https://doi.org/10.5125/jkaoms.2017.43.2.120. (PMID: 10.5125/jkaoms.2017.43.2.120284621975410424) Dişel U, Beşen AA, Özyılkan Ö, Er E, Canpolat T (2012) A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol 48:e2–e3. https://doi.org/10.1016/j.oraloncology.2011.07.030. (PMID: 10.1016/j.oraloncology.2011.07.03021865077) Allegra A, Oteri G, Alonci A, Bacci F, Penna G, Minardi V, Maisano V, Musolino C (2014) Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. J Craniomaxillofac Surg 42:279–282. https://doi.org/10.1016/j.jcms.2013.05.014. (PMID: 10.1016/j.jcms.2013.05.01423800756) Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, Ciuffreda L, Scoletta M (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200. https://doi.org/10.1093/annonc/mdr039. (PMID: 10.1093/annonc/mdr03921427065) Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2009) Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 140:1259–1265. https://doi.org/10.14219/jada.archive.2009.0049. (PMID: 10.14219/jada.archive.2009.004919797556) Hayano H, Kuroshima S, Sasaki M, Tamaki S, Inoue M, Ishisaki A, Sawase T (2020) Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice. Bone 135:115308. https://doi.org/10.1016/j.bone.2020.115308. (PMID: 10.1016/j.bone.2020.11530832142911) Aghaloo TL, Tetradis S (2017) Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases. J Oral Maxillofac Surg 75:129–142. https://doi.org/10.1016/j.joms.2016.07.019. (PMID: 10.1016/j.joms.2016.07.01927569557) Yazdi PM, Schiodt M (2015) Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 119:416–422. https://doi.org/10.1016/j.oooo.2014.12.024. (PMID: 10.1016/j.oooo.2014.12.02425697927) Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23:826–836. https://doi.org/10.1359/jbmr.080205. (PMID: 10.1359/jbmr.08020518558816) Saad F, Brown JE, Van Poznak C et al (2012) Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23:1341–1347. https://doi.org/10.1093/annonc/mdr435. (PMID: 10.1093/annonc/mdr43521986094) Wick A, Bankosegger P, Otto S, Hohlweg-Majert B, Steiner T, Probst F, Ristow O, Pautke C (2022) Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin Oral Investig 26:2839–2852. https://doi.org/10.1007/s00784-021-04261-4. (PMID: 10.1007/s00784-021-04261-434812959) Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575. https://doi.org/10.1016/j.joms.2005.07.010. (PMID: 10.1016/j.joms.2005.07.01016243172) O’Ryan FS, Lo JC (2012) Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg 70:1844–1853. https://doi.org/10.1016/j.joms.2011.08.033. (PMID: 10.1016/j.joms.2011.08.03322595135) Sawair FA, Shayyab MH, Al-Rababah MA, Saku T (2009) Prevalence and clinical characteristics of tori and jaw exostoses in a teaching hospital in Jordan. Saudi Med J 30:1557–1562. (PMID: 19936420) AlZarea BK (2016) Prevalence and pattern of torus palatinus and torus mandibularis among edentulous patients of Saudi Arabia. Clin Interv Aging 11:209–213. https://doi.org/10.2147/cia.s100282. (PMID: 10.2147/cia.s100282269663574771409) Ueda N, Aoki K, Shimotsuji H, Nakashima C, Kawakami M, Imai Y, Kirita T (2021) Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer. J Bone Miner Metab 39:623–630. https://doi.org/10.1007/s00774-020-01195-x. (PMID: 10.1007/s00774-020-01195-x33420576) Goldman ML, Denduluri N, Berman AW, Sausville R, Guadagnini JP, Kleiner DE, Brahim JS, Swain SM (2006) A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer. Oncology 71:306–308. https://doi.org/10.1159/000106451. (PMID: 10.1159/00010645117657174) Corraini P, Heide-Jørgensen U, Schiødt M, Nørholt SE, Acquavella J, Sørensen HT, Ehrenstein V (2017) Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. Cancer Med 6:2271–2277. https://doi.org/10.1002/cam4.1173. (PMID: 10.1002/cam4.1173289412105633555) García-García AS, Martínez-González JM, Gómez-Font R, Soto-Rivadeneira A, Oviedo-Roldán L (2010) Current status of the torus palatinus and torus mandibularis. Med Oral Patol Oral Cir Bucal 15:e353–e360. https://doi.org/10.4317/medoral.15.e353. (PMID: 10.4317/medoral.15.e35319767716) Allegra A, Innao V, Pulvirenti N, Musolino C (2019) Antiresorptive agents and anti-angiogenesis drugs in the development of osteonecrosis of the jaw. Tohoku J Exp Med 248:27–29. https://doi.org/10.1620/tjem.248.27. (PMID: 10.1620/tjem.248.2731080196) Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van Den Wyngaert T (2019) Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 127:117–135. https://doi.org/10.1016/j.oooo.2018.09.008. (PMID: 10.1016/j.oooo.2018.09.00830393090) Ottesen C, Schiodt M, Jensen SS, Kofod T, Gotfredsen K (2022) Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation. Oral Surg Oral Med Oral Pathol Oral Radiol 133:165–173. https://doi.org/10.1016/j.oooo.2021.06.003. (PMID: 10.1016/j.oooo.2021.06.00334275774) |
| فهرسة مساهمة: | Keywords: Bisphosphonate-associated osteonecrosis of the jaw; Bone density conservation agents; Diphosphonates; Exostoses; Surgery |
| المشرفين على المادة: | 0 (Bone Density Conservation Agents) |
| تواريخ الأحداث: | Date Created: 20240228 Date Completed: 20240817 Latest Revision: 20240905 |
| رمز التحديث: | 20240906 |
| مُعرف محوري في PubMed: | PMC11330401 |
| DOI: | 10.1007/s10006-024-01214-5 |
| PMID: | 38418702 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1865-1569 |
|---|---|
| DOI: | 10.1007/s10006-024-01214-5 |